The promotion and reimbursement practices for the medtech company’s implantable CPAP alternative are under scrutiny.

During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

Inspire Medical Systems, Inc. INSP delivered an earnings per share (EPS) of $1.15 in fourth-quarter 2024, up 134.7% from the ...

In a highly anticipated conference call, Inspire Medical Systems reported an impressive fourth quarter and full year 2024 ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...

Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zoetis (ZTS – Research Report), Inspire Medical Systems ...

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally ...

Inspire Medical Systems, Inc. ( NYSE: INSP) Q4 2024 Earnings Conference Call February 10, 2025 5:00 PM ET Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive ...

CEO Tim Herbert highlighted milestones in 2024, including surpassing 90,000 patients treated with Inspire therapy, FDA approval of the Inspire V neurostimulator, and achieving full-body MRI ...